Bancheng Chen, Chenchen Wu, Yan Liao, Hao Hu, Xiaojuan Liu, Chao Chen, Xiaoming Liu, Lin Wu, Xiaofan Chen, Bo Yu
{"title":"Bioinformatic analysis and experimental validation implicate STAT2-mediated angiogenic responses in rosacea pathogenesis","authors":"Bancheng Chen, Chenchen Wu, Yan Liao, Hao Hu, Xiaojuan Liu, Chao Chen, Xiaoming Liu, Lin Wu, Xiaofan Chen, Bo Yu","doi":"10.1007/s00403-025-03915-7","DOIUrl":null,"url":null,"abstract":"<div><p>Rosacea is a chronic skin condition characterized by facial erythema, flushing, and telangiectasia. Abnormalities in the vascular responses are associated with the development of rosacea. Our analysis of the GSE65914 dataset revealed differential expression of angiogenesis-related genes in rosacea lesions classified rosacea samples with distinct angiogenic molecular patterns. Further investigation of immune infiltration characteristics across angiogenic patterns identified unique immune signatures associated with VEGFA<sup>high</sup> MMP9<sup>low</sup> and VEGFA<sup>low</sup> MMP9<sup>high</sup> subtypes. Moreover, STAT2 proteins were higher in the VEGFA<sup>high</sup> MMP9<sup>low</sup> pattern group. Increased expression of STAT2 was confirmed in rosacea patients and in the mice model of rosacea induced by LL37. Knockdown of STAT2 suppressed the tube formation ability of human umbilical vein endothelial cells, which implicated STAT2 participated in regulating angiogenic responses. In conclusion, our study characterized rosacea subtypes by distinct angiogenic molecular patterns and found that STAT2 may play a critical role in the regulation of angiogenic responses in rosacea. These insights may provide a promising target of rosacea therapies.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Dermatological Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00403-025-03915-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rosacea is a chronic skin condition characterized by facial erythema, flushing, and telangiectasia. Abnormalities in the vascular responses are associated with the development of rosacea. Our analysis of the GSE65914 dataset revealed differential expression of angiogenesis-related genes in rosacea lesions classified rosacea samples with distinct angiogenic molecular patterns. Further investigation of immune infiltration characteristics across angiogenic patterns identified unique immune signatures associated with VEGFAhigh MMP9low and VEGFAlow MMP9high subtypes. Moreover, STAT2 proteins were higher in the VEGFAhigh MMP9low pattern group. Increased expression of STAT2 was confirmed in rosacea patients and in the mice model of rosacea induced by LL37. Knockdown of STAT2 suppressed the tube formation ability of human umbilical vein endothelial cells, which implicated STAT2 participated in regulating angiogenic responses. In conclusion, our study characterized rosacea subtypes by distinct angiogenic molecular patterns and found that STAT2 may play a critical role in the regulation of angiogenic responses in rosacea. These insights may provide a promising target of rosacea therapies.
期刊介绍:
Archives of Dermatological Research is a highly rated international journal that publishes original contributions in the field of experimental dermatology, including papers on biochemistry, morphology and immunology of the skin. The journal is among the few not related to dermatological associations or belonging to respective societies which guarantees complete independence. This English-language journal also offers a platform for review articles in areas of interest for dermatologists and for publication of innovative clinical trials.